{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:43:13Z","timestamp":1792503793133,"version":"4.5.0"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This is a phase II subprotocol of the National Cancer Institute-Children\u2019s Oncology Group Pediatric Molecular Analysis for Therapy Choice (MATCH) precision oncology platform trial evaluating selpercatinib, a RET inhibitor, in children and young adults aged 1-21\u2009years with relapsed or refractory solid tumors with RET alterations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Selpercatinib was given at 90\u2009mg\/m2\/dose (maximum dose 160\u2009mg\/dose) orally twice daily for 28-day cycles until progression or intolerable toxicity. The primary aim was to determine the objective response rate, and secondary objectives included assessing the tolerability of selpercatinib and estimating the progression-free survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two patients with papillary thyroid carcinomas harboring CCD6C-RET fusions matched to the subprotocol. One patient was deemed ineligible as they had not yet experienced tumor recurrence. The other patient enrolled and received selpercatinib at 90\u2009mg\/m2\/dose, completing all 26 cycles of protocol therapy and achieving a partial response confirmed by central imaging review. There were no dose-limiting toxicities, and the patient experienced only grade 1 adverse events attributable to selpercatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>There was a low match and accrual rate on this MATCH subprotocol, resulting in early termination of the study. The basis for low accrual was likely multifactorial, including the overall rarity of this genetic alteration across pediatric tumor types and accelerated FDA approval of selpercatinib in children \u226512\u2009years old prior to the opening of this subprotocol.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number<\/jats:title>\n                    <jats:p>ClinicalTrials.gov (NCT04320888)<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>IRB approved<\/jats:title>\n                    <jats:p>Initial September 14, 2020<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag382","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:35:29Z","timestamp":1791891329000},"source":"Crossref","is-referenced-by-count":0,"title":["Phase II study of selpercatinib in children and young adults with RET-altered tumors: arm N of the NCI-COG Pediatric MATCH trial (APEC1621N)"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5361-7683","authenticated-orcid":false,"given":"Andrea T","family":"Franson","sequence":"first","affiliation":[{"name":"C.S. Mott Children\u2019s Hospital, University of Michigan Medical School , Ann Arbor, MI 48109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7122-953X","authenticated-orcid":false,"given":"Samara L","family":"Potter","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, The Ohio State University College of Medicine , Columbus, OH 43205,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Mickey","family":"Williams","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9447-7701","authenticated-orcid":false,"given":"Sinchita","family":"Roy-Chowdhuri","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3855-0166","authenticated-orcid":false,"given":"David R","family":"Patton","sequence":"additional","affiliation":[{"name":"Center for Biomedical Informatics and Information Technology, NCI, NIH , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2047-5699","authenticated-orcid":false,"given":"Brent D","family":"Coffey","sequence":"additional","affiliation":[{"name":"Center for Biomedical Informatics and Information Technology, NCI, NIH , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-3123","authenticated-orcid":false,"given":"Joel M","family":"Reid","sequence":"additional","affiliation":[{"name":"Mayo Clinic , Rochester, MN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0516-6280","authenticated-orcid":false,"given":"Jin","family":"Piao","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Saguilig","sequence":"additional","affiliation":[{"name":"Children\u2019s Oncology Group Statistical Center , Monrovia, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6772-6581","authenticated-orcid":false,"given":"Todd A","family":"Alonzo","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California , Los Angeles, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L","family":"Berg","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Cancer and Hematology Centers, Baylor College of Medicine , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-9449","authenticated-orcid":false,"given":"Nilsa C","family":"Ramirez","sequence":"additional","affiliation":[{"name":"Ann and Robert H. Lurie Children\u2019s Hospital , Chicago, IL,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9998-5326","authenticated-orcid":false,"given":"Elizabeth","family":"Fox","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital , Memphis, TN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-1402","authenticated-orcid":false,"given":"Brenda J","family":"Weigel","sequence":"additional","affiliation":[{"name":"St. Jude Children\u2019s Research Hospital , Memphis, TN,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3602-1375","authenticated-orcid":false,"given":"Douglas S","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Seattle Children\u2019s Hospital, University of Washington , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-8331","authenticated-orcid":false,"given":"Margaret M","family":"Mooney","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-4954","authenticated-orcid":false,"given":"Naoko","family":"Takebe","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James V","family":"Tricoli","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A","family":"Janeway","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-7955","authenticated-orcid":false,"given":"Nita L","family":"Seibel","sequence":"additional","affiliation":[{"name":"Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, National Cancer Institute , Bethesda, MD,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8775-3501","authenticated-orcid":false,"given":"Donald Williams","family":"Parsons","sequence":"additional","affiliation":[{"name":"Texas Children\u2019s Cancer and Hematology Centers, Baylor College of Medicine , Houston, TX,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"key":"2026102009173757200_oyag382-B1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1089\/thy.2017.0059","article-title":"Molecular testing for oncogenic gene alterations in pediatric thyroid lesions","volume":"28","author":"Mostoufi-Moab","year":"2018","journal-title":"Thyroid"},{"key":"2026102009173757200_oyag382-B2","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026102009173757200_oyag382-B3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102009173757200_oyag382-B4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"2026102009173757200_oyag382-B5","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf149.1746","article-title":"OR28-05 selpercatinib in pediatric and adolescent patients with RET-altered solid tumors: safety and efficacy results from the phase 1\/2 LIBRETTO-121 study","volume":"9","author":"Laetsch","year":"2025","journal-title":"J Endocr Soc"},{"key":"2026102009173757200_oyag382-B6","doi-asserted-by":"crossref","first-page":"10022","DOI":"10.1200\/JCO.2024.42.16_suppl.10022","article-title":"Safety and efficacy of selpercatinib in pediatric patients with RET-altered solid tumors: updated results from LIBRETTO-121","volume":"42","author":"Morgenstern","year":"2024","journal-title":"JCO"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag382\/71904227\/oyag382.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag382\/71904227\/oyag382.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag382\/71904227\/oyag382.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T13:17:46Z","timestamp":1792502266000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag382\/8913750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":6,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag382","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,7]]},"article-number":"oyag382"}}